ArticleCurrent microbiology2025
Prevalence and Genetic Profiling of Second-line Drug Resistant Tuberculosis at the Tertiary Care Center of Northern India.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Burden of multidrug-resistant and extensively drug-resistant tuberculosis in China, India and Russia: estimates from the GBD 2023 study.Journal of thoracic disease · 2026Article
- Reliable, accessible, cost-effective, & easy (RACE) diagnostic modality: A key for elimination of tuberculosis.The Indian journal of medical research · 2025Review
- Molecular insights of drug-resistant tuberculosis: genetic mutations and their profile.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant TB (XDR-TB) complicates control efforts. We investigated the prevalence and genetic patterns of pre-XDR and XDRTB, by employing second-line line probe assays (SL-LPA). This prospective cohort study was conducted at the Intermediate Reference Laboratory, from November 2023 to May 2024. We screened 1253 samples via Genxpert followed by florescence microscopy, and mutational/resistance analysis via the GenoType MTBDRplus/FL-LPA (first line-line probe assay) and MTBDRsl/SL-LPA for the mutation patterns. We identified 355 rifampicin drug-resistant TB isolates, 260 of which were smear positive samples obtained for FL-LPA and SL-LPA. Finally, 255 MDR/RR-TB patients were analyzed and 73(28.62%) patients exhibited second-line drug (SLD) resistance. Among the cases, 65(89.04%) were found to be resistant solely to fluoroquinolones (FQ), whereas 3(4.11%) were resistant only to aminoglycosides (pre-XDR TB). However, 5(6.8%) patients were resistant to both FQ and aminoglycosides (XDR-TB). We also found that males 44(60.37%) were more affected by SLD resistance than 29(39.72%) females, however SLD resistant females were younger than males (26.97 ± 14.84 vs. 35.84 ± 15.26, p = 0.016). The number of previously treated patients were significantly greater in SLD-resistance than in SLD-sensitive patients. The most common mutation in the gyrA gene was D94G, which was observed in 52(71.23%) cases, followed by A90V in 10(13.69%), D94N and D94A in 4(5.48%), whereas the rrs gene presented the rrsMUT1 (A1401G) mutation in 7(9.58%) and the rrsMUT2(G1484T) mutation in 1(1.37%) of SLD-resistant patients. The alarming rate of SLD-resistance among MDR-TB patients highlights the need for improved management strategies focused on early and accurate diagnosis of DR-TB.
Indexed as
Identifiers
40053148What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.